Trial Profile

Tivozanib - Real World Experience on Tolerability, Patient Reported Outcomes and QoL in 1st line aRCC - T-REX

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivozanib (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions
Acronyms T-REX
Sponsors EUSA Pharma

Most Recent Events

06 Jun 2023 Results (n=32) assessing we assessed the quality of life of tivozanib in real-world patient population in Germany using NCCN-FACT FKSI-19 (FKSI-19) and tailored PRO-CTCAE questionnaires presented at the 59th Annual Meeting of the American Society of Clinical Oncology
31 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com